FDA grants accelerated approval to zongertinib for non-squamous NSCLC
On August 8, 2025, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinas
On August 8, 2025, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinas
FDA approved Papzimeos, the first immunotherapy for use in adults with recurrent respiratory papillomatosis.
This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program
Correction Issued for the Novum IQ Large Volume Pumps, Syringe Pumps
FDA approved Papzimeos, the first immunotherapy for use in adults with recurrent respiratory papillomatosis.
Molecular tumor boards (MTBs) are multidisciplinary meetings of specialists dedicated to analyzing biomarker test results to provide personalized treatment recommendations. However, global disparities in the…
FDA approved Papzimeos, the first immunotherapy for use in adults with recurrent respiratory papillomatosis.
A monthly newsletter for oncology/hematology fellows, junior faculty and scientists
Neuhaus Chocolates NV of Vlezenbeek, BELGIUM has initiated a voluntary recall for : Belgian Chocolate Moments Smurfs ‘Popping Milk Chocolates with Cookies, because it contains…
Meeting information for FDA/The Osteosarcoma Institute (OSI) Workshop
DermaRite Industries, LLC is voluntarily recalling individual lots of products in the table below due to microbial contamination identified as Burkholderia cepecia.